Form 4: Jaguar Health Grants Executive Stock, Options

Jaguar Health, Inc. granted its Chief of Staff, Chief Compliance Officer, and General Counsel, Jonathan S. Wolin, 11,740 restricted stock units and 11,740 stock options.

Summary

• Jonathan S. Wolin, Chief of Staff, Chief Compliance Officer & General Counsel of Jaguar Health, Inc. (JAGX), was granted 11,740 restricted stock units (RSUs) and 11,740 stock options.
• The RSUs were granted on December 11, 2025, at a price of $0, and represent a contingent right to receive one share of common stock per unit, vesting on December 11, 2026.
• The stock options were granted on December 11, 2025, with an exercise price of $1.44, and will vest ratably on a monthly basis over 12 months from the grant date, expiring on December 11, 2035.
• Both grants were approved by the issuer's board of directors on December 11, 2025, and issued under the company's 2014 Stock Incentive Plan.
• Following these transactions, Mr. Wolin beneficially owns 11,938 shares of common stock directly and 11,740 stock options directly.
• A 25-for-1 reverse stock split was effected on March 24, 2025, which provides context for the reported share numbers.

Sentiment

Score: 7

Explanation: The filing reports standard executive compensation through equity grants, which is generally positive for aligning management incentives with shareholder interests. No negative news is present, but it's a routine disclosure rather than a significant positive catalyst.

Positives

• The grants align management's interests with shareholders by providing equity incentives.
• The vesting schedules for both RSUs (December 11, 2026) and options (ratably over 12 months) encourage long-term retention and performance from a key executive.

Risks

• The value of the granted equity is subject to the future performance of Jaguar Health, Inc.'s stock price.
• The options' exercise price of $1.44 means they will only be 'in the money' if the stock price exceeds this value, introducing market risk.

Future Outlook

The grants are designed to incentivize the executive over the next 12 months and beyond, with options expiring in 2035, suggesting a long-term alignment with company performance.

Management Comments

• The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
• The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Industry Context

Equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industry, particularly for companies like Jaguar Health, Inc., to attract, retain, and motivate talent, aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The use of both restricted stock units (RSUs) and stock options is a common compensation structure in the biotech industry, balancing immediate equity participation with long-term performance incentives.
• Vesting periods, such as the 12-month ratable vesting for options and one-year cliff vesting for RSUs, are typical for executive compensation plans, comparable to practices at similar-stage biopharmaceutical companies.
• The exercise price of $1.44 for options is set at the market price on the grant date, which is standard practice to ensure options have intrinsic value only if the stock appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value through equity ownership. Dilution from future share issuance upon RSU vesting and option exercise is a consideration.
• Employees: The grants to a key executive may signal the company's strategy for retaining top talent.

Next Steps

• Jonathan S. Wolin's restricted stock units will vest on December 11, 2026.
• Jonathan S. Wolin's stock options will vest ratably on a monthly basis over 12 months from December 11, 2025, contingent on continued employment.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of restricted stock units and stock options. While these grants align management's interests with shareholders, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The filing is a standard disclosure and does not present a catalyst for significant price movement, thus a 'hold' recommendation is appropriate based solely on this document.

Keywords

Jaguar Health, JAGX, Form 4, SEC Filing, Stock Grant, Stock Options, Restricted Stock Units, Executive Compensation, Jonathan S. Wolin, Equity Incentive Plan, Corporate Governance